Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Evolus reported Q3 2026 global net revenue of $78.0 million, a 13% increase year-over-year, driven by growth in its Jeuveau toxin and HA gel portfolio. The company achieved its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million and reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million.
Term
Q3 2026
“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company. Jeuveau® remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”
David Moatazedi, President and Chief Executive Officer
“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity. Our partnership with IBSA to develop and commercialize Profhilo® in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”
David Moatazedi, President and Chief Executive Officer
Regeneron Pharmaceuticals Insider George L. Sing Sells $20.4M of Stock
George L. Sing sold 21,129 shares of Regeneron Pharmaceuticals, Inc. at $960.57 to $970.18 a share (average $964.38) in 9 transactions, worth $20.4M in total on Nov 2, 2026. Shares held after the trade: 25,147 (-0.8%).
Lesaka Technologies reported its Q1 2027 results, showing continued operations across its Merchant, Consumer, and Enterprise segments. The company maintains significant credit facilities with Nedbank and RMB to support its microlending and merchant finance operations, while managing a complex capital structure involving various restricted stock and employee option plans.
WesBanco, Inc. filed its Q4 2026 investor presentation to be used at various conferences and events throughout the fourth quarter. The presentation highlights the company's $28.5 billion in assets, its organic loan growth strategy, and its focus on expanding into high-growth markets while maintaining a disciplined expense culture.
Acadia Healthcare reported Q3 2026 revenue of $895.3 million, a 5.1% increase year-over-year, driven by strong performance in acute inpatient psychiatric facilities. While net income slightly decreased to $34.5 million, the company raised its full-year 2026 financial guidance based on positive operational momentum and facility expansions.
Term
Q3 2026
“Acadia delivered strong results in the third quarter, and our positive momentum is driving our increased full-year guidance. We remain focused on our key priorities, including expanding access to quality patient care and consistent operational execution with financial discipline.”
Alto Ingredients reported Q3 2026 net income of $12.7 million on net sales of $257.9 million, driven by core operations and 45Z tax credit earnings. The company reduced its debt by $26.5 million year-to-date and expects to generate at least $20 million in net 45Z tax credits for the full year 2026.
Term
Q3 2026
“We delivered positive gross profit, income from operations, net income and adjusted EBITDA for the third quarter demonstrating the earnings power of our core operations with 45Z tax credit earnings adding to an already solid foundation.”
Bryon McGregor, President and Chief Executive Officer
“Through our efforts to lower our carbon scores at our Columbia facility and Pekin dry mill, we now expect to generate a minimum of $20 million, net of monetization costs, in 2026.”
Bryon McGregor, President and Chief Executive Officer
Matson reported strong Q3 2026 results with net income of $209.4 million and revenue of $1.11 billion, driven by high demand and elevated freight rates in its China service. The company raised its full-year outlook, expecting Q4 2026 consolidated operating income to be approximately 50% higher than the prior year period.
Term
Q3 2026
“Matson had a stronger-than-expected third quarter. Our China service performed well, with its speed and reliability serving as important differentiators amid continued pressure on global shipping networks and congestion at key Asia ports.”
Matt Cox, Matson’s Chairman and Chief Executive Officer
“Looking ahead, we expect the strong demand and elevated freight rates we experienced in our China service in the third quarter to continue through year end and into early 2027.”
Matt Cox, Matson’s Chairman and Chief Executive Officer
OnKure Therapeutics reported third quarter 2026 financial results and provided updates on its PI3Kα pan-mutant-selective inhibitor pipeline. The company remains on track to submit IND applications for OKI-355 (vascular anomalies) and OKI-345 (breast cancer) in the first half of 2027, while also launching the PANORAMA disease registry.
“We continue to advance the development of next-generation PI3Kα pan-mutant-selective inhibitors through our pipeline, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. Both of our lead programs remain on track for IND submissions in the first half of 2027.”
Nicholas Saccomano, Ph.D., President and Chief Executive Officer
“People living with vascular anomalies remain underserved, and we believe OnKure has an opportunity to help shape the future of treatment for this community. Mutations in the PIK3CA gene drive a range of vascular malformations, providing a compelling rationale for our development of OKI-355, which is designed to provide broad coverage across these mutations.”
Autonation CEO and Director Michael Mark Manley Buys $1.03M of Stock
Michael Mark Manley, CEO and Director, bought 5,600 shares of Autonation, Inc. at $183.84 to $184.65 a share (average $184.11) in 2 transactions, worth $1.03M in total on Nov 2, 2026. Shares held after the trade: 157,186 (+1.2%).
Revolution Medicines reported its first product revenue of $197.6 million for the quarter ended September 30, 2026, following the commercialization of RASONQUE® (daraxonrasib). The company significantly strengthened its balance sheet, ending the period with approximately $3.65 billion in cash and marketable securities, though it continues to operate with a substantial accumulated deficit of $4.37 billion.
Vir Biotechnology reported third-quarter 2026 financial results, ending the period with $901 million in cash and investments. The company highlighted upcoming Phase 3 data for its hepatitis delta program and the receipt of FDA Fast Track designation for its oncology candidate VIR-5500.
“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology. We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year. With momentum across both areas, we believe Vir Bio is well positioned to deliver meaningful value for patients and stakeholders.”
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
Green Thumb Industries Inc. reported total assets of $2.85 billion as of September 30, 2026, with cash and cash equivalents increasing to $316 million from $274 million at year-end 2025. The company maintained a strong balance sheet with accumulated earnings of $180.9 million, though total shareholders' equity slightly decreased to $1.86 billion due to changes in share capital and contributed deficit.
For the quarter ended September 30, 2026, Sinclair reported total revenue of $893 million and net income attributable to Sinclair of $43 million, a significant improvement from the $1 million loss in the prior year period. The company's balance sheet shows a reduction in total debt to $4.04 billion from $4.38 billion at the end of 2025, while cash and cash equivalents decreased to $659 million.
Trex Company reported net sales of $359.5 million for the third quarter of 2026, a significant increase from $285.3 million in the prior year period. Despite higher sales, nine-month net income decreased slightly to $175.8 million compared to $188.1 million in 2025, primarily due to increased cost of sales and higher selling, general, and administrative expenses.
Relay Therapeutics reported third quarter 2026 financial results, highlighting a cash position of approximately $849 million. The company provided clinical updates for its breast cancer and vascular anomalies programs, including an expected enrollment completion for the Phase 3 ReDiscover-2 trial in mid-2027.
Term
Q3 2026
“This quarter, we are very pleased by the pace of enrollment of our ReDiscover-2 trial for second-line breast cancer and also look forward to sharing updated ReInspire data for vascular anomalies at ASH. In addition, we continue to prepare for our frontline breast cancer trial testing the selective-selective combination of zovegalisib and atirmociclib, and we were highly encouraged by the data we saw from Pfizer’s FourLight-1 trial, which we believe showed the potential advantage of a CDK4-selective approach.”
Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics
HubSpot reported Q3 2026 revenue of $947.6 million, a 17% increase year-over-year, driven by 18% growth in subscription revenue. The company also reported a significant increase in GAAP net income to $83.0 million and expanded its customer base to over 311,000 while repurchasing $237.2 million of its common stock during the quarter.
Term
Q3 2026
“We are still in the early stages of a massive shift with AI, and we’re transforming HubSpot to lead in the Outcomes Era. AI is fundamentally changing software, from tools that help people do work to agents that do the work and deliver outcomes. We're transforming our product, pricing, go-to-market, and how we operate to capture this opportunity, and we made meaningful progress across these areas this quarter.”
Jeremy Yarwood, CSO, sold 9,051 shares of Neogen Corp at $12.67 a share, worth $115K in total on Nov 4, 2026. Shares held after the trade: 0 (-100.0%).
electroCore reported record third-quarter 2026 net sales of $9.7 million, a 12% increase year-over-year driven by growth in U.S. prescription sales within the VA channel. The company significantly reduced its GAAP net loss by 61% to $1.3 million and improved its Adjusted EBITDA loss by 67% to $0.7 million.
“This quarter reflects the early stages of a more efficient commercial organization. This quarter we delivered record net sales of $9.7 million, up approximately 12% from a year ago, while spending less to do it, leading to the lowest operating loss in our history. More importantly, we have evidence that the transformation is working. We are deliberately prioritizing profitable, sustainable long-term growth over short-term results, which underpins our confidence in accelerating revenue growth and an inflection point in positive Adjusted EBITDA in 2027.”
Joshua Lev, Co-Chief Executive Officer, President, and Chief Financial Officer
Monro, Inc. entered into an amendment to its Rights Agreement to extend the expiration date of its shareholder rights plan (poison pill) from November 6, 2026, to November 1, 2027. The Board of Directors approved the extension to protect the company and its shareholders while it continues an ongoing review of strategic alternatives.
ZoomInfo reported third quarter 2026 financial results with GAAP revenue of $308.8 million, a 3% decrease year-over-year. The company highlighted strength in its million-dollar customer cohort and continued focus on capital allocation, including the repurchase of 2.5 million shares and $34.8 million of its Senior Notes.
Term
Q3 2026
“ZoomInfo is central to how leading GTM teams and their AI agents get work done, and our headless context layer is now grounding AI agents across dozens of platforms our customers already use. Our largest customers continue to invest and grow with us, with our million dollar customer cohort the strongest it has ever been from an ACV and a logo perspective.”
Sera Prognostics reported Q3 2026 financial results, highlighting a 54% sequential increase in PreTRM test volume and a five-fold increase since Q1 2026. The company secured Medicaid coverage for its test in Florida, following a similar win in Illinois, and ended the quarter with $72.8 million in cash and marketable securities.
Term
Q3 2026
“The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution. We delivered strong growth in physician adoption and test volume, saw expanded reimbursement through a second state Medicaid coverage win in Florida, advanced our commercial payer initiatives, and continued to strengthen our clinical and health economic evidence base.”
Zhenya Lindgardt, President and Chief Executive Officer
Pacific Biosciences of California Financial Results
Pacific Biosciences reported Q3 2026 revenue of $40.6 million, driven by demand for its Revio and Vega sequencing systems. Alongside the results, the company announced that CFO Jim Gibson has stepped down and transitioned to an advisory role, with CEO Mark Van Oene serving as interim CFO during a search for a permanent successor.
Term
Q3 2026
“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities. SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth.”
Mark Van Oene, President and Chief Executive Officer
Arcus Biosciences reported total revenues of $67 million for the nine months ended September 30, 2026, a significant decrease from $214 million in the prior year period, primarily due to lower license and development services revenue. The company recorded a net loss of $347 million for the first nine months of 2026, compared to a net loss of $247 million in 2025, as operating expenses continued to outpace revenue.
Silvaco Group reported third quarter 2026 financial results with revenue of $16.3 million and a GAAP net loss of $4.6 million. The company highlighted record bookings in its TCAD segment and issued strong Q4 guidance, expecting 35% sequential revenue growth driven by new Tier-1 customer wins.
Term
Q3 2026
“I am pleased with Silvaco’s Q3 results and Q4 guidance. In Q3, bookings strength was driven by a significant new Tier-1 FTCO customer and 4 tier-1 customer wins for Jivaro Pro. We also engaged with two of the largest global technology companies with our Agentic AI offerings. Looking forward, we expect strong revenue growth, with 35% sequential growth expected in Q4, 17% growth year-over-year in 2026 and mid-to-high teens growth in 2027.”
Walden Rhines, Silvaco’s Chief Executive Officer
“As the business accelerates, we are achieving meaningful financial milestones. Net cash used in operations improved significantly in Q3, we ended Q3 with the most unrestricted cash on the balance sheet since Q2’25 and we are guiding to record revenue in Q4. We expect our higher growth expectations to continue expanding our profitability and cash generation in 2027.”
Chris Zegarelli, Silvaco’s Chief Financial Officer
Meta Platforms Director Marc L. Andreessen Sells $12.8M of Stock
Marc L. Andreessen, Director, sold 20,951 shares of Meta Platforms, Inc. at $606.85 to $613.88 a share (average $609.74) in 8 transactions, worth $12.8M in total on Nov 2, 2026. Shares held after the trade: 0 (-100.0%).
Sunrun reported Q3 2026 financial results, highlighting a record 75% storage attachment rate and a return to growth in its direct installation business. The company generated $56 million in cash (excluding safe harbor investments) and revised its full-year 2026 cash generation guidance to approximately $200 million.
Term
Q3 2026
“Sunrun has returned its direct business to growth, with installations increasing 9% year-over-year. Sunrun is the nation's largest Residential Independent Power Producer. We hit a 75% attachment rate of storage assets, the highest in our history. The need for affordable, reliable power has never been more evident, and our storage-first offering is meeting it. We are positioning the business for strong growth, bringing on some of the best talent in the industry and scaling deliberately, with a focus on customer experience and asset quality. And as that engine scales, we're aiming to unlock new ways to monetize the network we've already built, from distributed power plant programs to emerging data center and grid edge applications, creating new streams of Cash Generation.”
Mary Powell, Sunrun’s Chief Executive Officer
“Q3 marked an important inflection point as we returned to growth in our direct business and expanded our Upfront Net Subscriber Value margins considerably. We delivered $56 million in Cash Generation in Q3, excluding investments in equipment for safe harbor activities, and expect higher Cash Generation in Q4 resulting in full-year Cash Generation of approximately $200 million.”
Chime Financial reported third-quarter 2026 revenue of $718 million, a 32% year-over-year increase, and achieved its third consecutive quarter of GAAP profitability with net income of $44 million. The company added 1.8 million net new Active Members over the past year, bringing the total to 10.9 million, driven by growth in its Chime Prime and lending businesses. Based on strong momentum in MyPay and Instant Loans, Chime raised its full-year 2026 financial outlook.
Term
Q3 2026
“This was our strongest quarter yet as a public company, and we are seeing structural improvements in our growth and profitability profile. We added a record 1.8 million net new Active Members over the past year, accelerated revenue growth to 32%, and delivered our third consecutive quarter of GAAP profitability. Chime Prime and our growing lending business are deepening primary account relationships and driving the strongest unit economics in our history. Our momentum gives us confidence to raise our outlook for the remainder of the year.”
Grindr Director George Raymond Zage III Sells $6.43M of Stock
George Raymond Zage III, Director, sold 500,000 shares of Grindr Inc. at $12.78 to $13.03 a share (average $12.87) in 2 transactions, worth $6.43M in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 6,127,743 (-2.7%).
Western Union reported third quarter 2026 results with GAAP revenue of $1.0 billion, a 2% decrease year-over-year. The company saw 8% growth in Branded Digital revenue and transaction growth of 21%, while overall earnings were impacted by a slowdown in the North America retail business and expenses related to its efficiency program.
Term
Q3 2026
“As we move through the second half of the year, we continue to make progress against our Beyond strategy. Importantly, the initiatives we launched in the second quarter are streamlining our cost structure and have begun to materialize in our financial results. At the same time, we continue to invest in growth, including expanding our digital capabilities, embedding AI across key operational processes, and advancing our stablecoin and next-generation money movement initiatives. We are beginning to see the impact of all of these efforts and remain confident in our ability to improve performance and create long-term shareholder value.”
Devin McGranahan, President and Chief Executive Officer
Blue Owl Capital Corporation reported Q3 2026 net investment income of $0.34 per share and an increased NAV per share of $14.32. The company declared a total dividend of $0.32 per share for the quarter and noted strong credit quality with no new non-accruals.
Term
Q3 2026
“We are very pleased with OBDC's results this quarter, resulting in a 10.3% annualized return on net income. Earnings continued to comfortably cover the base dividend and NAV increased 40 basis points. Our borrowers have sustained year-over-year growth and credit quality remained strong, with no new issuers added to non-accrual”
Craig W. Packer, Chief Executive Officer
“Looking ahead, we are well positioned to benefit from improved market economics as investments originated at wider spreads begin to fund, while higher base rates could provide an additional tailwind as our floating-rate loans reset.”